» Articles » PMID: 18472967

Constitutive Activation of Raf-1 Induces Glioma Formation in Mice

Overview
Journal Neoplasia
Publisher Elsevier
Specialty Oncology
Date 2008 May 14
PMID 18472967
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

In human glioblastoma multiforme (GBM), RAS activity is upregulated in the majority of the tumors. Furthermore, the levels of phospho-mitogen-activated protein kinase/extracellular signal regulated kinase (MAPK/ERK), a downstream effector of RAS, are also increased. In mice, activated KRas cooperates with the loss of INK4a-ARF locus or with activated Akt to induce gliomas, confirming an important role for this pathway in glioma biology. However, to correctly target therapies against the RAS signaling pathway, it is necessary to identify the effectors that contribute to RAS-mediated gliomagenesis. In this study, we investigated the contribution of RAF signaling in glioma oncogenesis. We find that the levels of RAF-1 and BRAF proteins and RAF kinase activity are increased in human GBM samples. We confirm the importance of this finding by demonstrating a causal role for a constitutively active Raf-1 mutant in glioma formation in mice. Specifically, we find that activated Raf-1 cooperates with Arf loss or Akt activation to generate gliomas similar to activated KRas under the same conditions. Our study suggests that the oncogenic effect of KRas in glioma formation may be transduced at least in part through Raf signaling and that therapeutic targeting of this pathway may be beneficial in glioma treatment.

Citing Articles

Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies.

Pouyan A, Ghorbanlo M, Eslami M, Jahanshahi M, Ziaei E, Salami A Mol Cancer. 2025; 24(1):58.

PMID: 40011944 PMC: 11863469. DOI: 10.1186/s12943-025-02267-0.


Vitamin D Relieves Epilepsy Symptoms and Neuroinflammation in Juvenile Mice by Activating the mTOR Signaling Pathway via RAF1: Insights from Network Pharmacology and Molecular Docking Studies.

Lu T, Chen X, Zhang Q, Shang K, Yang X, Xiang W Neurochem Res. 2024; 49(9):2379-2392.

PMID: 38837094 DOI: 10.1007/s11064-024-04176-y.


hsa-miR-34a-5p enhances temozolomide anti-tumoral effects on glioblastoma: in-silico and in-vitro study.

Shadbad M, Baghbanzadeh A, Baradaran B EXCLI J. 2024; 23:384-400.

PMID: 38655096 PMC: 11036064. DOI: 10.17179/excli2023-6404.


Pediatric diffuse hemispheric glioma H3 G34-mutant with gains of the BRAF locus: An illustrative case.

Marlow C, Cuoco J, Hoggarth A, Stump M, Apfel L, Rogers C Rare Tumors. 2023; 15:20363613231168704.

PMID: 37056711 PMC: 10088409. DOI: 10.1177/20363613231168704.


Anticancer Mechanism of Flavonoids on High-Grade Adult-Type Diffuse Gliomas.

Wong S, Kamarudin M, Naidu R Nutrients. 2023; 15(4).

PMID: 36839156 PMC: 9964830. DOI: 10.3390/nu15040797.


References
1.
Solit D, Garraway L, Pratilas C, Sawai A, Getz G, Basso A . BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2005; 439(7074):358-62. PMC: 3306236. DOI: 10.1038/nature04304. View

2.
Balan V, Leicht D, Zhu J, Balan K, Kaplun A, Singh-Gupta V . Identification of novel in vivo Raf-1 phosphorylation sites mediating positive feedback Raf-1 regulation by extracellular signal-regulated kinase. Mol Biol Cell. 2006; 17(3):1141-53. PMC: 1382304. DOI: 10.1091/mbc.e04-12-1123. View

3.
Repasky G, Chenette E, Der C . Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?. Trends Cell Biol. 2004; 14(11):639-47. DOI: 10.1016/j.tcb.2004.09.014. View

4.
Basto D, Trovisco V, Lopes J, Martins A, Pardal F, Soares P . Mutation analysis of B-RAF gene in human gliomas. Acta Neuropathol. 2005; 109(2):207-10. DOI: 10.1007/s00401-004-0936-x. View

5.
Kimura E, Nikiforova M, Zhu Z, Knauf J, Nikiforov Y, Fagin J . High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003; 63(7):1454-7. View